What CALCIUMFOLINAT biosyn Treats: Main Uses and Benefits

This medication is commonly used to provide essential protective support following high-intensity cancer treatments, particularly those using high-dose Methotrexate. It is applied in addressing systemic toxicity symptoms that can affect healthy cells, especially symptoms related to bone marrow suppression and injury to the gastrointestinal tract. This supportive measure may be part of symptomatic management that helps maintain a sense of stability when symptoms are more noticeable.

CALCIUMFOLINAT is relevant for easing symptom burden in several distinct clinical contexts. It is applied across domains where additional symptomatic support is needed, and is relevant for: assisting the therapeutic goals of certain combination chemotherapy regimens; addressing specific types of megaloblastic anemia caused by a lack of active folate; and serving as an antidote for acute, severe systemic toxicity following overexposure to non-cancer medications that interfere with folate processes.

“This medication is primarily used to provide supportive relief, and helps with managing symptoms that interfere with daily comfort during complex medical episodes.”

This use contributes to easing the overall symptom load during periods of heightened symptoms and supports the patient during difficult episodes by easing distress.

---

Quick Fact: Relevant for Systemic Toxicity Symptoms

Eligibility and Contraindications

The eligibility for CALCIUMFOLINAT biosyn (Leucovorin Calcium) is defined by official regulatory labeling, outlining specific populations that can or must not use the medicine.

Absolute Contraindications

CALCIUMFOLINAT biosyn is formally contraindicated and must not be used in patients diagnosed with pernicious anemia or any other megaloblastic anemia that is due to a Vitamin B12 deficiency. This exclusion is necessary to prevent the risk of masking the anemia while allowing neurological damage to progress. The medicine is also strictly contraindicated for patients with a known hypersensitivity to Leucovorin Calcium or any of the formulation's components.

Population Restrictions

Use is permitted in adults and pediatric patients for its labeled indications, primarily as a rescue agent after specific high-dose chemotherapy. However, caution is required for patients with renal insufficiency or compromised hepatic function, as these conditions may affect the overall supportive management protocol. When used in specific combination regimens, such as with 5-Fluorouracil, treatment is restricted and must be suspended if a patient develops severe gastrointestinal toxicity.

Pregnancy and Lactation

There are no adequate and well-controlled clinical studies in pregnant women. Use during pregnancy or lactation is restricted and should occur only when the specialist determines the potential benefit clearly justifies the potential risk.

Official Interaction Profile for CALCIUMFOLINAT biosyn (Leucovorin Calcium)

The official interaction profile for Leucovorin Calcium is structured around its documented modulating effects on co-administered medicinal products, as specified in government regulatory documents.

Interaction Classification	Interacting Agents / Conditions	Officially Documented Outcome
Contraindicated Use	Megaloblastic Anemia (B12 deficiency)	Formally contraindicated (may mask anemia while neurological symptoms progress). Intrathecal administration is strictly prohibited.
Toxicity Enhancement	5-Fluorouracil (5-FU)	Enhances toxicity, leading to more severe and prolonged gastrointestinal effects; elderly patients are noted as being at higher risk.
Efficacy Reduction	Folic Acid Antagonists (e.g., Methotrexate, Trimethoprim)	Reduces or nullifies the therapeutic effect of the antagonist when administered excessively or inappropriately.
Exposure Modification	Anti-epileptic Drugs (e.g., Phenytoin, Phenobarbital)	May decrease plasma concentrations of these drugs, which is a consideration for susceptible children due to potential seizure risk.

Timing and Procedural Restrictions: Mandatory timing rules prohibit mixing Leucovorin in the same intravenous infusion with 5-Fluorouracil due to physical incompatibility. Administration must also be avoided within two hours of Glucarpidase dosing due to the risk of metabolic interference. Furthermore, official labeling requires avoiding foods, drinks, or drugs that increase urinary acidity during high-dose Methotrexate therapy with Leucovorin rescue.

How CALCIUMFOLINAT biosyn Works: Mechanism of Action

Bypassing Folate Enzyme Blockade

CALCIUMFOLINAT (folinic acid) is structurally a reduced folate that undergoes metabolic activation to cofactors required for the one-carbon metabolism pathway, thereby bypassing the reaction catalyzed by the enzyme Dihydrofolate Reductase (DHFR). This action provides the necessary reduced folates to support de novo synthesis of DNA precursors, resulting in the preservation of nucleic acid synthesis and repair capacity in non-target cells.

---

Enhancing Targeted Enzyme Inhibition

When utilized in combination with certain anti-replicative drugs, the active metabolite of CALCIUMFOLINAT stabilizes the inhibitory complex formed by the drug metabolite and the enzyme Thymidylate Synthase (TS). This mechanism locks the enzyme in an inactive state, leading to a depletion of thymidine nucleotides, which are essential for DNA replication.

---

Modulating Nucleic Acid Synthesis

The combined effects of folate cofactor provision and/or enzyme inhibition directly modulate the de novo synthesis of DNA and RNA building blocks (purines and pyrimidines). This action influences physiological processes characterized by high cellular turnover, resulting in two distinct physiological consequences: the maintenance of synthetic capacity in non-target cells and the enhanced inhibition of replication in target cells.

Official Administration Guidelines

Calcium Folinate (Leucovorin) must be administered strictly according to established protocols, particularly when used in combination with cytotoxic agents or for specific deficiency conditions. The medicine is available as a solution for injection/infusion and in tablet form.

Approved Routes and Forms

Route	Typical Form	Constraint
Intravenous (IV)	Injection/Infusion	Max rate of 160 mg/minute due to calcium content.
Intramuscular (IM)	Injection	Used for megaloblastic anemia and some rescue protocols.
Oral (PO)	Tablets	Parenteral route required for doses exceeding 25 mg (due to absorption saturation).

Dosing and Scheduling

The most common use, Methotrexate (MTX) Rescue, requires time-critical administration. The initial dose (e.g., 15 mg or 6-12 mg/m²) must begin 12 to 24 hours after the start of the MTX infusion. Subsequent doses are typically repeated every 6 hours for a total course duration that lasts until the MTX plasma concentration is below a specific therapeutic threshold (e.g., <0.05 mu mol/L). For use with 5-Fluorouracil (5-FU), the dose (e.g., 200 mg/m²) is given under various cyclic regimens.

Preparation and Special Conditions

For intravenous infusion, the solution must be diluted with standard solutions such as 0.9% Sodium Chloride or 5% Glucose. Calcium Folinate must not be mixed in the same syringe or infusion with 5-FU. It is also forbidden for the medicine to be administered via the intrathecal route.

Research evidence / Overview of studies for CALCIUMFOLINAT biosyn

---

Evidence for use in Chronic Pain (e.g., Neuropathic Pain, Fibromyalgia)

CALCIUMFOLINAT biosyn was studied for conditions characterized by fluctuating or episodic manifestations of pain, such as neuropathic pain and fibromyalgia. Research examined short-term data, primarily through controlled clinical trials, where outcomes related to physical discomfort (like reported pain intensity scores) were measured. The findings describe patterns observed in the studies, with some trials describing measurements of reported pain intensity. However, these patterns were observed in some studies but not others, and the sample size was generally modest.

Evidence for use in Major Depressive Disorder (MDD)

Studies monitored the use of the product, often applied in research contexts involving fluctuating or unstable symptoms of MDD, primarily as an added treatment to standard antidepressant therapy. Research explored short- to medium-term data, looking at outcomes related to systemic or functional imbalance, specifically measuring changes using standardized depression rating scales. Research highlights changes measured during the study period, but findings were mixed regarding the consistency and extent of these reported changes across the available trials.

Evidence for use in Bipolar Disorder (BPD)

CALCIUMFOLINAT biosyn was studied for conditions presenting with cycles of stability and flare-ups in Bipolar I Disorder, with trials focusing on acute manic or mixed episodes, or on maintenance. Research explored data related to outcomes describing episodic or acute changes using specific mood scales. Studies report how symptoms evolved in the observed populations during periods of acute mood activity, with findings describing patterns observed in the measured mood scores.

---

Long-term studies and follow-up

Research focusing on long-term follow-up beyond the duration of the initial clinical trials is limited. Long-term outcomes are not fully established in this context, meaning there is limited information for long-term outcomes regarding the sustained daily-life impact. It is not yet clear whether the observed patterns of symptom change persist after the study period.

Evidence in special populations

Data for certain groups remain insufficient. Most research results apply only to the populations studied, which are predominantly non-elderly adults. Few data are available for children, adolescents, older adults, or populations with complex co-existing medical conditions. Research in pregnancy and breastfeeding populations is not fully established.

What is still uncertain about CALCIUMFOLINAT biosyn

Overall, evidence quality varies across studies, and sample sizes were modest across several key trials. Comparative evidence is lacking to understand how the product’s reported profile relates to other established approaches. Evidence highlights what is known — and what is still uncertain, particularly regarding long-term outcomes and consistency of findings across heterogeneous patient groups. The research provides context but not individual predictions about personal outcomes.

Key Studies & References Systematic Review and Meta-Analysis of CALCIUMFOLINAT as Adjunctive Therapy in Treatment-Resistant Major Depressive Disorder (MDD)

Common questions about CALCIUMFOLINAT biosyn (FAQ)

---

Q: What are the most commonly reported side effects when CALCIUMFOLINAT biosyn is used alone, not with other medicines?

A: When CALCIUMFOLINAT biosyn is used by itself, and not in combination with other potent treatments, its intrinsic toxicity is generally considered low. According to official documents, the most frequently observed reaction is pyrexia (fever) following injection, which is classified as uncommon (affecting up to 1 in 100 people). Other effects like seizures and fainting (syncope) are listed as rare occurrences, typically only following high doses.

---

Q: Is a low-grade fever considered a normal or common side effect of CALCIUMFOLINAT biosyn injection?

A: A fever (pyrexia) after an injection of CALCIUMFOLINAT biosyn is listed in official product information as an uncommon side effect. This classification means it is not expected to affect most patients.

---

Q: Does CALCIUMFOLINAT biosyn cause changes in mood, such as depression or agitation, in some people?

A: Official safety documents indicate that psychiatric disorders, including agitation and depression, are possible, but are classified as rare side effects. This means these effects are reported to affect up to 1 in 1,000 people and typically occur only following high doses of the medicine.

---

Q: Does the injection or infusion form of CALCIUMFOLINAT biosyn need to be protected from light for storage?

A: Yes, the original, unopened vials of the medicine must be stored in the outer carton. This is a requirement in official guidelines to protect the medicine from light.

---

Q: What has the research evidence shown about the use of CALCIUMFOLINAT biosyn in older adult patients (geriatrics)?

A: Official safety and interaction information notes that older adults are at a greater risk for severe gastrointestinal toxicity, such as severe diarrhea, when this medicine is administered as part of a combination treatment with 5-fluorouracil. Official research data for this specific population is not fully established.

---

Q: Are there any food-related restrictions or guidelines mentioned in the official product information?

A: Yes, official labeling includes a mandatory warning about certain foods or drinks. When the medicine is used as a 'rescue' agent after high-dose Methotrexate therapy, official labeling requires avoiding foods, drinks, or drugs that increase the acidity of urine.

---

Q: What is the information about using CALCIUMFOLINAT biosyn for pediatric patients (children and adolescents)?

A: The medicine is indicated for use in children and adolescents to help lessen the toxicity caused by certain medications, like folic acid antagonists. Official documents note caution because CALCIUMFOLINAT biosyn may potentially reduce the effectiveness of some anti-epileptic drugs, which could increase seizure risk in susceptible children.

---

Q: Does CALCIUMFOLINAT biosyn contain any common allergens like lactose?

A: The solution prepared for injection or infusion typically contains only the active ingredient (Leucovorin Calcium) along with standard excipients like sodium chloride and water. The composition of inactive ingredients (excipients) can vary between the injection and tablet forms. Patients should refer to the official label for the specific dosage form and batch to confirm its exact contents.

---

Q: What is the physical appearance of the CALCIUMFOLINAT biosyn solution for injection?

A: The CALCIUMFOLINAT biosyn solution prepared for injection or infusion is officially described in regulatory documents as a clear and yellowish solution. The official guidance specifies that if the solution appears cloudy or particles are observed, it should be discarded.

---

Q: What are the general expectations for the duration of CALCIUMFOLINAT biosyn treatment for its primary uses?

A: The expected duration depends entirely on the specific purpose of the treatment. For its use as a rescue agent following high-dose Methotrexate, administration is time-critical and continues until the concentration of Methotrexate in the blood falls below a specified threshold. For its use as a modulating agent with chemotherapy like 5-FU, it is administered according to various pre-determined, cyclic treatment regimens.

---

Q: What are the indications for using CALCIUMFOLINAT biosyn to prevent folate deficiency?

A: According to official therapeutic indications, this medicine can be administered to help prevent and treat folate deficiency in specific situations. This includes when folate deficiency cannot be corrected by taking supplements orally, such as during total parenteral nutrition (IV feeding) or in cases of severe malabsorption disorders.

---

Q: Is there a known effect of CALCIUMFOLINAT biosyn on the kidneys or liver?

A: While the medicine's own effect on these organs is not typically listed as a primary side effect, caution is formally required for patients with pre-existing renal insufficiency (kidney problems) or compromised hepatic function (liver problems), which influences the overall management protocol.

---

Q: What information is available about CALCIUMFOLINAT biosyn and its potential effects on fertility?

A: Official regulatory documents state there are no adequate and well-controlled clinical studies conducted that specifically address the medicine’s potential effects on fertility in humans.

---

Q: Can CALCIUMFOLINAT biosyn cause skin reactions like palmar-plantar erythrodysaesthesia?

A: Official documents list allergic reactions, including severe anaphylactoid reactions and skin conditions like urticaria (hives or rash), as very rare. Specific, less common skin reactions, such as palmar-plantar erythrodysaesthesia, are not explicitly listed in the core safety profile of the drug.

How to Store and Dispose of CALCIUMFOLINAT biosyn

Official regulatory documents define specific conditions for storing and disposing of CALCIUMFOLINAT biosyn to ensure product integrity and public safety.

Storage Requirements

The unopened vials must be stored in a refrigerator at a temperature between 2 C and 8 C and must not be frozen. The vial must be kept in the outer carton to protect the medicine from light. The medicine must be kept out of the sight and reach of children.

Once the product is diluted, it should be used immediately from a microbiological perspective. If immediate use is not possible, the solution should typically be stored for no longer than 24 hours at 2 C to 8 C.

Disposal Instructions

Any unused or expired medicinal product must be disposed of in accordance with local requirements. It is strictly prohibited to throw away the medicine via wastewater or household waste.